Table 6

Characteristics of patients with pre-existing immune-mediated inflammatory disease (IMID) according to the reason for referral (disease flare or other)

All (N=45)Disease flare (N=31)Other (N=14)P value*
Inpatients, N (%)177100.002
Outpatients, N (%)28244
Male, N (%)9540.33
Female, N (%)362610
Vaccine type, N (%)†0.45
 BNT162b2372611
 mRNA-1273550
 ChAdOx1202
 Ad26.COV2.S101
Doses received prior to IMID diagnosis0.25
 121174
 2211110
 Full-schedule+booster†330
Age, mean±SD62±1361±1367±90.12
Comorbidities, median (range)4 (1–7)4 (1–7)5 (3–7)0.04
Type of comorbidity, N (%) of patients
Cardiovascular diseases24 (53)15 (48)9 (64)0.65
Respiratory diseases8 (18)5 (16)3 (21)0.67
Metabolic disorders9 (20)8 (26)1 (7)0.15
Gastrointestinal diseases11 (24)6 (19)5 (36)0.24
Renal diseases3 (7)2 (6)1 (7)0.93
Neurological diseases5 (11)3 (10)2 (14)0.65
Endocrine diseases21 (47)15 (48)6 (43)0.73
Urogenital diseases3 (7)1 (3)2 (14)0.17
Non-inflammatory MSK diseases13 (29)9 (29)4 (29)0.97
Neoplasms1 (2)1 (3)0 (0)0.55
Dermatological diseases4 (9)2 (6)2 (14)0.39
Psychiatric diseases6 (13)4 (13)2 (14)0.89
Ophtalmological diseases1 (2)1 (3)0 (0)0.55
Haematological disorders2 (4)2 (6)0 (0)0.93
ENT diseases1 (2)1 (3)0 (0)0.55
>1 IMID6 (13)5 (16)1 (7)0.41

  • *Patients who developed a disease flare versus patients with other vaccine-related diagnoses. P values were calculated with χ2 test or Mann-Withney U test as needed. BNT162b2, vaccine developed by Pfizer/BioNTech; mRNA1273, vaccine developed by Moderna; ChAdOx1 nCoV-19, vaccine developed by AstraZeneca; Ad26.COV2.S, vaccine developed by Janssen.

  • †Booster dose was BNT162b2 in 3/3 patients.

  • ENT, ears, nose and throat; MSK, musculoskeletal.